Video

Dr. Scher on Key Findings From the COU-AA-302 Trial

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.

Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone acetate plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) prior to the administration of chemotherapy.

This trial reported several important findings, Scher believes. First, he states, the trial established that a hormonal agent is capable of delaying time to progression and potentially could improve survival in men with mCRPC. Additionally, the trial established an important new endpoint for clinical trials in mCRPC through the validation of radiographic progression-free survival (rPFS).

This endpoint was established through the application of predefined assays that standardized the interpretation of bone scans. In the trial, a correlation between rPFS and overall survival was observed in a reproducible and consistent fashion. This endpoint will serve as a useful tool in future trials, Scher notes, especially for comparing agents and in trials seeking regulatory approval.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD